TYMIANSKI, MICHAEL,LI, RONGWEN,GARMAN, JONATHAN DAVID
申请号：
EP11833072
公开号：
EP2621945A4
申请日:
2011.09.28
申请国别(地区):
EP
年份:
2014
代理人:
摘要：
The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.
